Curaxins for use in treating carcinogen-induced cancer
The present invention relates to the treatment of breast cancer which is estrogen receptor positive (ER + ) and/or human epidermal growth factor receptor 2 positive (HER2) and/or progesterone receptor positive (PR) and/or facilitates chromatin transcription positive (FACT+) with a curaxin, including curaxin 137. The present invention also pertains to a method of identifying a subject who has a breast cancer tumor and is likely to respond to treatment with a curaxin.
1. A method for treating a carcinogen-induced cancer in a subject in need thereof, comprising administering to the subject an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt or hydrate thereof, wherein:
the carcinogen is a genotoxic carcinogen and
the cancer is selected from colon, renal and uterine cancer.
2. The method of claim 1 , wherein the cancer is colon cancer.
3. The method of claim 1 , wherein the cancer is renal cancer.
4. The method of claim 1 , wherein the cancer is uterine cancer.
5. The method of claim 1 , wherein the genotoxic carcinogen is a hydrazine.
6. The method of claim 5 , wherein the hydrazine is dimethylhydrazine.
7. The method of claim 6 , wherein the dimethylhydrazine is 1,2-dimethylhydrazine.